Belumosudil ( DrugBank: Belumosudil )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
51	Scleroderma	2

51. Scleroderma

---

Clinical trials : 523 /  Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04680975 (ClinicalTrials.gov)	December 24, 2020	11/12/2020	Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis	A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)	Diffuse Cutaneous Systemic Sclerosis	Drug: Belumosudil	Kadmon Corporation, LLC	NULL	Active, not recruiting	18 Years	N/A	All	15	Phase 2	United States
2	NCT03919799 (ClinicalTrials.gov)	July 9, 2019	21/11/2018	KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis	A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis	System; Sclerosis;Diffuse Cutaneous Systemic Sclerosis	Drug: Belumosudil (KD025);Drug: Placebo	Kadmon Corporation, LLC	NULL	Active, not recruiting	18 Years	100 Years	All	60	Phase 2	United States